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days with ≥ 50% decreased household productivity (mean BL:10.5, C/W:1.2), RA inter-
ference with household productivity (mean BL:6.2, C/W:2.0) and days missed per 
month of family/social/leisure activity (mean BL:5.8, C/W:0.7). ConClusions: In 
the RAPID1 OLE, CZP Q2W plus MTX maintained improvements in workplace and 
household productivity and increased social activity participation over > 4yrs.
PMS87
Continued iMProveMentS in WorkPlaCe and HouSeHold ProduCtivity 
WitH CertolizuMab Pegol treatMent in axial SPondyloartHritiS, 
inCluding ankyloSing SPondylitiS and non-radiograPHiC axial 
SPondyloartHritiS: 48-Week reSultS froM tHe raPid-axSPa Study
van der Heijde D.1, Braun J.2, Rudwaleit M.3, Purcaru O.4, Kavanaugh A.5
1Leiden University Medical Centre, Leiden, The Netherlands, 2Rheumazentrum Ruhrgebiet, Herne, 
Germany, 3Endokrinologikum Berlin, Berlin, Germany, 4UCB Pharma, Brussels, Belgium, 5UCSD, 
San Diego, CA, USA
objeCtives: Investigate certolizumab pegol (CZP) effect on workplace and house-
hold productivity up to 48 weeks (wks) in patients (pts) with axial spondyloarthritis 
(axSpA), including ankylosing spondylitis (AS, meeting modified New York criteria) 
and non-radiographic axSpA (nr-axSpA). Methods: The ongoing RAPID-axSpA 
trial (NCT01087762) is double-blind and placebo-controlled to Wk24 and dose-
blind to Wk48. Pts had active axSpA, according to ASAS criteria, including AS and 
nr-axSpA. Pts originally randomized to CZP (200mg Q2W or 400mg Q4W, following 
400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in dose-blind 
phase; placebo pts entering dose-blind phase were re-randomized to CZP loading 
dose, followed by CZP 200mg Q2W or 400mg Q4W. The validated arthritis-specific 
Work Productivity Survey (WPS; administered Q4W) assessed the impact of axSpA 
on workplace and household productivity. WPS responses (LOCF imputation) in 
pts originally randomized to CZP in the full analysis set (FAS) are summarized 
descriptively over 48 wks. Results: A total of 325 pts were randomized, of which 
218 were assigned to CZP 200mg Q2W or CZP 400mg Q4W. 69.4% and 74.9% of pts 
were employed at baseline (BL) in the CZP 200mg Q2W and CZP 400mg Q4W groups, 
respectively. By Wk48, employed CZP pts reported reduced workplace absenteeism 
(Wk48: mean 0.4 and 0.1 days missed/month for CZP 200 mg Q2W and 400 mg 
Q4W, respectively vs BL: mean 2.3 and 1.4 days/month) and presenteeism (Wk48: 
mean 1.0 and 1.6 days with reduced productivity/month vs BL: mean 5.8 and 4.7 
days/month). Continued improvements in both CZP groups to Wk48 were also 
observed in household productivity and participation in social/leisure activities. 
Similar improvements were seen in AS and nr-axSpA populations. ConClusions: 
The initial improvements with CZP in workplace and household productivity and 
increased participation in social/leisure activities observed over 24 wks were con-
tinued to Wk48 in axSpA, AS and nr-axSpA pts.
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objeCtives: To examine the effect of certolizumab pegol (CZP) on workplace and 
household productivity up to 48 weeks (wks), in patients (pts) with active psoriatic 
arthritis (PsA). Methods: The ongoing RAPID-PsA trial (NCT01087788) is double-blind 
and placebo-controlled to Wk24 and dose-blind to Wk48. Pts had active PsA and had 
failed ≥ 1 DMARD. Pts originally randomized to CZP (200mg Q2W or 400mg Q4W, follow-
ing 400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in dose-blind 
phase; placebo pts entering dose-blind phase were re-randomized to CZP loading dose, 
followed by CZP 200mg Q2W or CZP 400mg Q4W. This publication reports data for pts in 
the randomised set (RS) originally randomized to CZP. The validated arthritis-specific 
Work Productivity Survey (WPS), administered Q4W from baseline (BL), assessed the 
impact of PsA on workplace and household productivity. WPS responses (LOCF impu-
tation) in both CZP groups are summarized descriptively over 48 wks. Results: 409 
pts were randomized, of which 273 were assigned to CZP 200mg Q2W or CZP 400mg 
Q4W. 87% of patients randomized to CZP completed to Wk48. 60.1% and 61.5% were 
employed at BL in the CZP 200mg Q2W and CZP 400mg Q4W groups, respectively. 
By Wk48, employed CZP pts reported reduced workplace absenteeism (Wk48: mean 
0.1 and 0.6 days missed/month for CZP 200mg Q2W and 400mg Q4W, respectively vs 
BL: mean 2.0 and 1.6 days/month) and presenteeism (Wk48: mean 0.8 and 1.9 days 
with reduced productivity/month vs BL: mean 5.2 and 5.1 days/month). CZP groups 
also reported improvements in household productivity and increased participation 
in social/leisure activities up to Wk48. ConClusions: The initial improvements with 
CZP in workplace and household productivity, and participation in social/leisure activi-
ties observed over 24 wks were maintained over 48 wks in PsA pts.
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objeCtives: To investigate the contribution of different socio-economic and clinical 
factors to absenteeism in the workplace in a population of Rheumatoid Arthritis (RA) 
patients currently in employment. Methods: A national retrospective survey was 
conducted in French RA patients (age < 60, either employed or unemployed) recruited 
by rheumatologists or who were members of a patients’ association (ANDAR). Patient-
reported outcomes, socio-economic characteristics and various measures of pro-
ductivity loss were collected using structured telephone interviews. Multivariate 
Wellness Survey, an Internet health survey administered to a representative sample 
of adults, were used. Respondents who reported experiencing OA, with the knee 
being the only joint affected, and who reported having had joint surgery in the past 
year were considered to have had a knee replacement. A matched control group was 
identified as a comparator to the knee replacement group by using a propensity 
score matching method (matching variables include demographics and health his-
tory). Knee replacement respondents and matched controls were compared with 
respect to the Short Form-36v2, activity impairment (from the Work Productivity 
and Activity Impairment questionnaire), and health care resource utilization using 
ANOVA tests. Results: A total of 102 respondents were identified as part of the 
knee replacement group (52.0% male, 57.9 years). Compared with matched con-
trols (n= 102), those in the knee replacement group reported significantly worse 
physical health status (42.5 vs. 47.6, p< .05) though equivalent mental health status 
(49.7 vs. 49.0, p= .67). Levels of activity impairment (38.0% vs. 27.0% impairment, 
p< .05) and health care resource utilization (physician visits: 7.3 vs. 4.5, p< .05; emer-
gency room visits: 0.6 vs. 0.2, p< .05; and hospitalizations: 0.6 vs. 0.2, p< .05) were 
all significantly higher among the knee replacement group relative to matched 
controls. ConClusions: These results suggest a significant burden among knee 
replacement respondents across both health status and economic outcomes. 
Improved management of these patients may have significant societal benefits.
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objeCtives: Inflammatory diseases such as rheumatoid arthritis (RA), psoriatic 
arthritis (PsA) and axial spondyloarthritis (axSpA) are associated with significant 
burden on patients’ (pts) health-related quality of life (HRQoL). The objective was to 
compare HRQoL across RA, PsA and axSpA populations. Methods: Baseline data 
used from: RA pooled RAPID1 (NCT00152386) and RAPID2 (NCT00160602), RAPID-
PsA (NCT01087788) and RAPID-axSpA (NCT01087762). Differences between SF-36 
HRQoL scores and US general population age/gender-matched population norms 
were calculated and descriptively compared between the overall RA, PsA and axSpA 
populations, PsA subpopulations with skin involvement (≥ 3% body surface area) and 
without, and axSpA subpopulations of ankylosing spondylitis (AS) and non-radio-
graphic axSpA (nr-axSpA). Physical function was assessed using HAQ-DI in RA and 
PsA, and was also compared between PsA subpopulations. Results: Comparison of 
SF-36 score decrement vs population norms (mean±SD) revealed axSpA pts (N= 317) 
experienced a higher burden on overall physical HRQoL (-19.3±7.5) compared to RA 
(N= 1535; -17.4±7.0) and PsA (N= 403; -16.6±8.0) pts, while RA pts reported a higher 
psychological burden (-11.3±11.2) compared to axSpA (-9.3±12.3) and PsA (-8.6±12.2) 
pts. Comparison of HAQ-DI scores revealed RA pts experienced greater difficulties in 
all physical function aspects assessed, compared to PsA pts. For axSpA pts, the burden 
of disease (SF-36 scores) was similar between AS and nr-axSpA subgroups. For PsA pts, 
comparison of HRQoL scores confirmed that skin involvement does not significantly 
add to the physical health burden of disease but adds to some of the psycho-social 
aspects (eg. social function). ConClusions: Trends suggested axSpA had the high-
est burden on overall physical HRQoL followed by RA and PsA, while the burden on 
overall mental HRQoL was highest in RA followed by axSpA and PsA. HRQoL burden 
in axSpA did not appear different between subpopulations, however the presence 
of skin involvement in PsA was associated with a higher burden on social function.
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objeCtives: In the RAPID1 randomized controlled trial (RCT; NCT00152386), certoli-
zumab pegol (CZP) every 2 weeks (Q2W) plus MTX provided rapid improvements in 
clinical measures, and workplace and household productivity over 52 weeks (wks) 
in patients (pts) with active rheumatoid arthritis (RA). We report the long-term effect 
of CZP+MTX Q2W on workplace and household productivity and social participation 
in RA pts from the RAPID1 open-label extension (OLE; NCT00175877). Methods: 
RAPID1 52-wk Completers and Wk16 Withdrawers were eligible for treatment in OLE 
with CZP 400mg Q2W +MTX, reduced per study protocol to 200mg Q2W +MTX after 
≥ 6 months in OLE. Workplace and household productivity were assessed through 
the validated RA-specific Work Productivity Survey (WPS-RA). WPS-RA responses 
(observed cases) are summarized for CZP RCT Completers who enrolled in OLE and 
completed WPS-RA at OLE completion/withdrawal visit (C/W). Results: Of CZP 
Completers who enrolled in OLE (N= 508), 388 remained at Wk208 (4yrs) and a subset 
of 290 completed WPS-RA at OLE C/W (after minimum 4.3 and maximum 6.2 years 
CZP treatment from RCT baseline [BL]). Of these pts at RCT BL (N= 267), 49% were 
employed outside the home, 21% were RA work-disabled, 14% were homemakers 
and 13% were retired. Employed pts reported long-term reductions in absenteeism 
[mean BL:3.7 (N= 131), C/W:0.1 (N= 129)], number of days with decreased productiv-
ity (presenteeism) (mean BL:7.8, C/W:0.4) and level of RA interference with work 
productivity (mean BL:5.0, C/W:1.3, on 0–10 scale) per month. Similar decreases 
were reported in the number of household work days missed (mean BL:8.1, C/W:1.0), 
